mardi 4 septembre 2012

The U.S. Food and Drug Administration recently
approved tbo-filgrastim to reduce the time certain patients receiving cancer
chemotherapy experience severe neutropenia, a decrease in infection-fighting
white blood cells called neutrophils.

Tbo-filgrastim is intended for use in adults
who have cancers other than blood or bone marrow cancers (non-myeloid
malignancies) and are taking chemotherapy drugs that cause a substantial
decrease in the production of neutrophils in the bone marrow. This reduction in
neutrophils may lead to infection and fever (febrile neutropenia).

Tbo-filgrastim stimulates the bone marrow to
increase the production of neutrophils. It is administered as an injection
beginning 24 hours after chemotherapy treatment.